Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Powell

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Nature Reviews. Endocrinology|November 27, 2021
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasiaRavi Savarirayan, Penny Ireland, Melita Irving, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
JCO Precision Oncology|December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyFunda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology|November 17, 2024
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trialLoren K Mell, Pedro A Torres-Saavedra, Stuart J Wong, et al.
JCO Precision Oncology|January 15, 2026
Olaparib in Patients With Solid Tumors With <i>ATM</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyDaniel R Carrizosa, Michael Rothe, Pam K Mangat, et al.
Nature Reviews. Endocrinology|November 27, 2021
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasiaRavi Savarirayan, Penny Ireland, Melita Irving, et al.
Pageof 9